MX2025002284A - Regímenes de dosificación de degradadores de receptores de estrógeno - Google Patents

Regímenes de dosificación de degradadores de receptores de estrógeno

Info

Publication number
MX2025002284A
MX2025002284A MX2025002284A MX2025002284A MX2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
dosage regimens
receptor degraders
degraders
cdk4
Prior art date
Application number
MX2025002284A
Other languages
English (en)
Inventor
Ronald Peck
Sheryl Maxine Gough
John J Flanagan
Sibyl Anderson
Ian Charles Anthony Taylor
Julia Perkins Smith
Weiwei Tan
Original Assignee
Arvinas Operations Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc, Pfizer filed Critical Arvinas Operations Inc
Publication of MX2025002284A publication Critical patent/MX2025002284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen métodos para tratar el cáncer que comprenden administrar a un sujeto una dosis diaria del Compuesto A, o una sal farmacéuticamente aceptable de esta, en combinación con un inhibidor de CDK4/6.
MX2025002284A 2022-08-31 2025-02-25 Regímenes de dosificación de degradadores de receptores de estrógeno MX2025002284A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263402651P 2022-08-31 2022-08-31
US202363443892P 2023-02-07 2023-02-07
US202363454422P 2023-03-24 2023-03-24
US202363454485P 2023-03-24 2023-03-24
US202363508503P 2023-06-15 2023-06-15
PCT/US2023/031574 WO2024049926A1 (en) 2022-08-31 2023-08-30 Dosage regimens of estrogen receptor degraders

Publications (1)

Publication Number Publication Date
MX2025002284A true MX2025002284A (es) 2025-06-02

Family

ID=88192329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025002284A MX2025002284A (es) 2022-08-31 2025-02-25 Regímenes de dosificación de degradadores de receptores de estrógeno

Country Status (10)

Country Link
EP (1) EP4580631A1 (es)
JP (1) JP2025530742A (es)
KR (1) KR20250076543A (es)
CN (1) CN120112291A (es)
AU (1) AU2023336057A1 (es)
CA (1) CA3266061A1 (es)
IL (1) IL319242A (es)
MX (1) MX2025002284A (es)
TW (2) TW202539669A (es)
WO (1) WO2024049926A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN119258223A (zh) * 2023-07-06 2025-01-07 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途
WO2026044127A1 (en) * 2024-08-22 2026-02-26 Arvinas Operations, Inc. Administration of cyp3a inhibitors in the treatment of cancer
WO2026128391A1 (en) * 2024-12-09 2026-06-18 Arvinas Operations, Inc. Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
KR20090052385A (ko) 2006-09-08 2009-05-25 화이자 프로덕츠 인크. 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
SI4197530T1 (sl) 2015-04-16 2026-03-31 Novartis Ag Tableta ribocikliba
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL303143A (en) * 2020-12-14 2023-07-01 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Also Published As

Publication number Publication date
CA3266061A1 (en) 2024-03-07
AU2023336057A1 (en) 2025-03-27
IL319242A (en) 2025-04-01
EP4580631A1 (en) 2025-07-09
TW202416991A (zh) 2024-05-01
WO2024049926A1 (en) 2024-03-07
CN120112291A (zh) 2025-06-06
TW202539669A (zh) 2025-10-16
KR20250076543A (ko) 2025-05-29
TWI866427B (zh) 2024-12-11
JP2025530742A (ja) 2025-09-17

Similar Documents

Publication Publication Date Title
MX2025000105A (es) Inhibidor de kras g12c para el tratamiento del cancer
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
PH12022553389A1 (en) Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
RU2015107877A (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
MX2023013715A (es) Regímenes de dosis de ecubectedina.
MX2023007058A (es) Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
WO2020033838A3 (en) Treatment of egfr-mutant cancer
NZ718766A (en) Anti-folr1 immunoconjugate dosing regimens
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
MX2025012780A (es) Tratamiento de la psoriasis con un inhibidor de bajo peso molecular del factor de necrosis tumoral alfa
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2025001181A (es) Regimenes de dosificacion que comprenden un inhibidor kat6 para el tratamiento de cancer
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
MX2023010394A (es) Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd.
BRPI1008000A2 (pt) composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.